PB-102-F02: Extension of the PB-102-F01 study (PRX-102 for ERT in Fabr

• Research type

  Research Study

• Full title

  An Extension of Phase 1/2, Open-Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks (9 Months) to Adult Fabry Patients

• IRAS ID

  134217

• Contact name

  Derralynn Hughes

• Contact email

  rmgvdah@ucl.ac.uk

• Sponsor organisation

  Protalix Ltd.

• Eudract number

  2013-002554-78

• Clinicaltrials.gov Identifier

  NCT01769001

• REC name

  London - Hampstead Research Ethics Committee

• REC reference

  13/LO/1104

• Date of REC Opinion

  29 Aug 2013

• REC opinion

  Favourable Opinion